Core Insights - In the first three quarters of this year, 624 out of 650 comparable QDII funds saw an increase in net value, representing a 96% success rate, while 26 funds experienced a decline [1] - The innovative drug sector has rebounded, leading to significant gains for funds heavily invested in this area, with top performers achieving returns exceeding 155% [1][2] - The top-performing QDII funds include Huatai-PB Hong Kong Advantage Selected Mixed Fund A and C, both achieving returns of 155.14% and 155.09% respectively [1] Fund Performance - 13 QDII funds recorded gains over 100%, with four from E Fund Management, including E Fund Global Pharmaceutical Industry Mixed Fund A and C, all surpassing 102% [2] - The top holdings of these funds include companies like Innovent Biologics, I-Mab Biopharma, and others in the innovative drug sector [2][3] - Other notable funds with over 100% returns include GF CSI Hong Kong Innovative Drug ETF and ICBC New Economy Mixed Fund, with respective gains of 112.80% and 104.12% [3] Fund Management - The current fund manager for Huatai-PB Hong Kong Advantage Selected Mixed Fund is Zhang Wei, who has extensive experience in the pharmaceutical sector [2] - E Fund's funds are managed by Yang Zhenxiao, who has a background in investment management and industry research [3] Sector Analysis - The innovative drug sector has shown strong performance, contributing to the significant gains of various QDII funds [3][4] - Funds with poor performance are primarily those focused on real estate and oil & gas sectors, as well as those tracking the S&P 500 healthcare index [5]

Core Insights - In the first seven months of the year, 600 out of 650 comparable QDII funds saw an increase in net value, representing a 92.31% success rate [1] - The innovation drug sector has rebounded, leading to significant gains for funds heavily invested in this area, with top-performing funds achieving returns exceeding 137% [1] - Several QDII funds, particularly those managed by E Fund, reported increases of over 90%, with four funds exceeding 95% returns, all focused on the innovative drug industry [2] Group 1: Fund Performance - The top-performing QDII funds include Huatai-PineBridge Hang Seng Innovation Drug ETF and others, with returns ranging from 100.48% to 87.44%, attributed to the strong performance of the innovation drug sector [3] - The leading QDII funds, such as Huatai-PineBridge and E Fund, have concentrated their investments in key innovative drug companies, including Innovent Biologics and Sinopharm [2][3] Group 2: Fund Management - The fund manager for the top-performing Huatai-PineBridge funds is Zhao Bei, who has been with the company since 2010 and currently leads the healthcare research team [3] - Zhang Wei, the manager of the top-performing Huatai-PineBridge Hong Kong Advantage Selected Mixed Fund, has a background in pharmaceutical research and has held various roles in the industry [1]

Group 1 - In the first half of the year, 576 out of 650 comparable QDII funds saw an increase in net value, representing 88.62% of the total [1] - The innovative drug sector has rebounded, leading to significant gains for funds heavily invested in this area, with top performers including Huatai-PB Hong Kong Advantage Selected Mixed Fund A and C, achieving returns of 86.00% and 85.64% respectively [1] - The top ten holdings of the leading funds include companies such as Rongchang Biologics, Kelun Pharmaceutical, and Innovent Biologics, indicating a strong focus on innovative pharmaceuticals [1] Group 2 - Thirteen QDII funds recorded gains exceeding 50% in the first half of the year, with four from E Fund Management, all focused on the innovative drug industry [2] - The top holdings of these high-performing funds include Hansoh Pharmaceutical, Kelun Pharmaceutical, and Innovent Biologics, showcasing a concentrated investment strategy in the healthcare sector [2] - Other ETFs such as GF CSI Hong Kong Innovative Drug ETF and Huatai-PB Hang Seng Innovative Drug ETF also reported gains above 50%, benefiting from the strong performance of the innovative drug sector [2] Group 3 - The top ten holdings of the ICBC New Economy Mixed Fund include Kelun Pharmaceutical, Innovent Biologics, and Hansoh Pharmaceutical, reflecting a strategic focus on high-growth healthcare companies [3] - Funds tracking indices related to Southeast Asian technology and oil sectors have underperformed, indicating sector-specific challenges within the QDII fund landscape [3] Group 4 - The performance rankings of QDII funds show that the top three funds are Huatai-PB Hong Kong Advantage Selected Mixed Fund C, A, and GF CSI Hong Kong Innovative Drug ETF, with net value growth rates of 86.00%, 85.64%, and 57.12% respectively [4] - The bottom-performing funds primarily track indices related to Southeast Asian technology and oil, with significant negative returns [4]